Acumen Pharmaceuticals, Inc. ABOS 深 沪
等待开盘 02-11 09:30:00 美东时间
2.47
-0.010
-0.40%
华盛通- 最 高2.575
- 今 开2.46
- 成交量 37.40万股
- 最 低 2.36
- 昨 收 2.48
- 总市值 1.50亿
- 52周最高 3.0499
- 市盈率 静 --
- 换手率 0.62%
- 52周最低 0.8551
- 委 比 75.10%
- 总股本 6057.34万
- 历史最高 26.98
- 量 比 0.76
- 振 幅 8.67%
- 历史最低 0.8551
- 每 手 1
- 风险率 0.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股牛股 | 机器人公司 RR飙升逾44%，公司与微软携手开发AI机器人技术；Redwire大涨近30%
机器人公司RR飙升逾44%，与微软携手开发AI机器人技术；Redwire大涨近30%，获巨额国防合同，最高可达1510亿美元；SATL大涨20%，出售卫星布局澳洲市场>>
01-28 19:42
美股大行评级 | 瑞穗上调希捷科技、西部数据、CoreWeave目标价；Trade Desk、W.R. Berkley遭多家大行下调目标价
今日重点评级关注：瑞穗：维持Syndax制药"跑赢大市"评级，目标价从410美元升至600美元；HC Wainwright & Co.：维持60 Degrees Pharmaceuticals, Inc."买入"评级，目标价从6美元升至24美元
01-28 10:59
Baker Hughes To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a comple...
01-27 20:55
BTIG Maintains Buy on Acumen Pharmaceuticals, Raises Price Target to $7
BTIG analyst Thomas Shrader maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and raises the price target from $4 to $7.
01-27 18:02
Acumen And JCR Pharma Collaborative Study Shows Improved Brain Distribution of AβO-Targeting Antibodies
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD),
2025-12-02 21:15
美股大行评级 | Stifel上调英伟达目标价升至250美元；大摩上调哔哩哔哩目标价升至27美元；NICE遭多家机构下调目标价
今日重点评级关注：Oppenheimer：维持Olema Pharmaceuticals"跑赢大市"评级，目标价从22美元升至45美元；Bernstein：维持Atlassian"跑赢大市"评级，目标价从290美元升至304美元
2025-11-19 11:01
Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer’s Disease
Acumen Pharmaceuticals announced the initiation of the open-label extension (OLE) phase of its Phase 2 ALTITUDE-AD trial for sabirnetug (ACU193), a therapy targeting soluble amyloid beta oligomers (AβOs) for early Alzheimer's disease (AD). All 542 participants who completed the 18-month placebo-controlled trial will receive sabirnetug intravenously every four weeks for 52 weeks. Sabirnetug, a humanized monoclonal antibody, demonstrated safety and...
2025-11-17 13:00
Earnings Scheduled For November 12, 2025
Companies Reporting Before The Bell • Hudbay Minerals (NYSE:HBM) is projected t...
2025-11-12 19:11
Acumen Pharmaceuticals Appoints New Board Chairman
Acumen Pharmaceuticals ( ($ABOS) ) has shared an announcement. On November 10, ...
2025-11-10 21:48
